MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Cumberland Pharmaceuticals Inc

Closed

4.75 -1.66

Overview

Share price change

24h

Current

Min

4.67

Max

5.04

Key metrics

By Trading Economics

Income

-365K

-1.9M

Sales

1.3M

10M

EPS

-0.136

Profit margin

-18.223

Employees

91

EBITDA

-1.9M

-1.8M

Dividends

By Dow Jones

Next Earnings

6 maj 2025

Market Stats

By TradingEconomics

Market Cap

-9.6M

63M

Previous open

6.41

Previous close

4.75

Technical Score

By Trading Central

Confidence

Bullish Evidence

Cumberland Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

24 kwi 2025, 23:54 UTC

Hot Stocks

Stocks to Watch: Alphabet, Intel, AppFolio

24 kwi 2025, 23:51 UTC

Market Talk

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 kwi 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 kwi 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 kwi 2025, 23:37 UTC

Top News

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 kwi 2025, 23:36 UTC

Top News

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 kwi 2025, 23:13 UTC

Top News
Earnings

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 kwi 2025, 23:09 UTC

Top News

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 kwi 2025, 23:02 UTC

Acquisitions, Mergers, Takeovers

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 kwi 2025, 23:02 UTC

Acquisitions, Mergers, Takeovers

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 kwi 2025, 22:51 UTC

Top News
Acquisitions, Mergers, Takeovers

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 kwi 2025, 22:48 UTC

Top News

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 kwi 2025, 22:47 UTC

Market Talk

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 kwi 2025, 22:38 UTC

Market Talk
Earnings

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 kwi 2025, 22:24 UTC

Earnings

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 kwi 2025, 22:24 UTC

Earnings

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 kwi 2025, 22:24 UTC

Market Talk
Earnings

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 kwi 2025, 22:23 UTC

Earnings

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 kwi 2025, 22:11 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

24 kwi 2025, 22:11 UTC

Market Talk
Earnings

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 kwi 2025, 22:09 UTC

Top News
Earnings

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 kwi 2025, 22:00 UTC

Market Talk
Earnings

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 kwi 2025, 21:39 UTC

Top News

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 kwi 2025, 21:24 UTC

Top News
Earnings

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 kwi 2025, 21:24 UTC

Top News
Earnings

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 kwi 2025, 21:23 UTC

Top News
Earnings

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 kwi 2025, 21:04 UTC

Earnings

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 kwi 2025, 21:03 UTC

Earnings

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 kwi 2025, 21:03 UTC

Earnings

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 kwi 2025, 21:02 UTC

Earnings

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Peer Comparison

Price change

Cumberland Pharmaceuticals Inc Forecast

Technical Score

By Trading Central

4.81 / 5.18Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Cumberland Pharmaceuticals Inc

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.